Screening and its consequences: an interview with Laura Esserman

Yesterday, Medscape Oncology published a brief interview with Dr. Laura Esserman (under the title “Cancer screening: when less is more“) that will be of interest to a number of our regular readers. … READ MORE …

The PSA screening controversy: two new pro/con presentations

The “New” Prostate Cancer InfoLink finds it fascinating how, while sticking to their guns about the value of “screening” healthy men for risk of prostate cancer, the two differing groups of advocates (those “for/pro” screening and those “against/con” its) are still failing to appropriately emphasize that they are using the word “screening” with differing intent. … READ MORE …

Urologists’ and radiation oncologists’ opinions on use of PSA test to screen for prostate cancer

A new study has provided data on the opinions of a random sample of 1,366 radiation oncologists and urologists with regard to the appropriate role of the PSA test in screening for prostate cancer (since the recommendation of a D grade for this test as a screening mechanism by the U.S. Preventive Services Task Force (USPSTF). … READ MORE …

Dr. David Agus on CBS’s “Morning Rounds”

So the role of prostate cancer screening got discussed on the CBS television program “Morning Rounds” on Saturday, by Dr. David Agus (a well-known urologic oncologist) and others. The context was the recent data on the “overuse” of the PSA test in men of 75+ years of age. … READ MORE …

From Amsterdam yesterday: European perspectives on the PSA screening issue

A report on the Medscape Oncology web site, published late yesterday, discusses two presentations given yesterday at the European Cancer Conference 2013, currently being held in Amsterdam. … READ MORE …

Appropriate use of the PSA test for assessing risk of prostate cancer

The following quotation is from the abstract of a recent review of the appropriate use of the PSA test in the assessment of risk for prostate cancer: … READ MORE …

Men’s opinions on PSA testing and the USPSTF guideline: does it apply to ME?

A study just published in the American Journal of Preventive Medicine suggests that “The new USPSTF recommendation against PSA testing in all men may be met with resistance” on the part of male consumers. … READ MORE …

New “six-point” statement about prostate cancer screening (redux)

Three weeks ago we mentioned a new six-point statement about PSA screening developed at a meeting in Melbourne, Australia. We would note that an updated set of information about this statement is now available on the BJU International web site. … READ MORE …

PSA testing, life and health insurance, and full disclosure

Many readers of this blog quite certainly have strong opinions about the position of the American Cancer Society (ACS) on use of the PSA test in assessment of risk for prostate cancer. However, one does have to give credit where credit is due on a related matter. … READ MORE …

Do the new data from the PCPT “change the game” when it comes to PSA screening?

So, with the new, 15-year survival data from the Prostate Cancer Prevention Trial (PCPT) published earlier this week (as discussed in a prior post), a key question for many is “Do these data significantly change the rationale for or against widespread screening for risk of prostate cancer?” … READ MORE …

New, six-point statement about PSA testing issued at PCWC

According to a report on the Bloomberg.com web site, attendees meeting at the Prostate Cancer World Congress (PCWC) in Melbourne, Australia have issued a new, six-point consensus statement about the use of the PSA test in the initial detection of prostate cancer. … READ MORE …

Decision aids, PSA-based screening, and male decision-making

According to a newly published study in JAMA Internal Medicine, web-based and print-based decision aids do help men to resolve their own internal conflicts about whether or not to get PSA tests for risk of prostate cancer … READ MORE …

New data from the Rotterdam section of the ERSPC: we need better tools

New follow-up data from the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer (ERSPC) trial at a median of 12.8 years suggest that the overall, absolute, prostate cancer-specific mortality rate was 1.8 per 1,000 men randomized or 0.18 percent. … READ MORE …

Risk for prostate cancer once screening ended (from the Göteborg cohort)

Many readers will want to be aware of a new article entitled “Incidence of prostate cancer after termination of screening in a population-based randomised screening trial” that has just been published in European Urology. … READ MORE …

What has your doctor told you about PSA testing?

According to a recent article in the Annals of Family Medicine, about 64 percent of 3,400 men aged between 50 and 74 years of age who participated in a survey conducted in 2010 stated that they had never had a conversation with their doctor about the pros and cons of PSA testing. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,132 other followers